The ELCC 2025 programme is now online!
The European Lung Cancer Congress 2025 will provide insights into the prevention, diagnosis and biology-informed, multi-disciplinary management of thoracic malignancies. Specifically, the Congress will include educational and scientific sessions covering:
- Prevention, screening and early diagnosis of thoracic tumours;
- Recent developments in molecular characterization of lung cancer;
- New breakthroughs from immunologic and targeted therapies;
- The evolving role of multidisciplinary decision-making in lung cancer;
- State of the art for NSCLC, SCLC, mesothelioma and mediastinal tumours
Learning objectives
- Learn about novel biomarker-guided treatment modalities for patients with lung cancer
- Be update on the optimal use of immunotherapy to treat patients with lung cancer
- Learn how to best sequence or combine multimodal therapies in common and rare thoracic tumours
- Update on novel and targeted therapies to treat patients with lung cancer.
- Review the emerging contribution of precision medicine, liquid biopsies, omics and AI technologies for the optimal management of thoracic tumors.
Accreditation
ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.